InspireMD, Inc. - 8-K Filing

InspireMD receives FDA approval for CGuard Prime for TCAR and reports Q3 2026 revenue of $2.24M with a net loss of $9.76M. (Items: 2.02 Results of Operations and Financial Condition On November 12, 2026, InspireMD, Inc, 8.01 Other Events Set forth below are certain financial results that the Company reported for the third quarter ended September 30, 2026: ●For the, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 12, 2026, 21:45 UTC

Tickers: $NSPR

Read the full article at SEC EDGAR

Part of the story InspireMD, Inc. - 8-K Filing (2 articles)

More Regulatory news

SCHWAB CHARLES CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:52 UTC
SPRUCE POWER HOLDING CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:52 UTC
Xterax Corp II - 10-Q Filing SEC EDGAR · November 12, 2026, 21:51 UTC
KinderCare Learning Companies, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:50 UTC
Finwise Bancorp - 8-K Filing SEC EDGAR · November 12, 2026, 21:49 UTC
TMC the metals Co Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:48 UTC
FACT II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:46 UTC
Marblegate Capital Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:46 UTC
Greenland Mines Ltd - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC
InspireMD, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:45 UTC